ClinicalTrials.gg
Enrolling by invitationNCT07387575SIRENUpdated Feb 4, 2026

Screening in Relatives With Elevated Risk for Unruptured Intracranial Aneurysms

An observational study in Intracranial Aneurysms and Subarachnoid Hemorrhage, Aneurysmal, sponsored by University of Novi Sad. Enrolling by invitation at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by University of Novi Sad · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to screen first-degree relatives of patients with aneurysmal subarachnoid hemorrhage using magnetic resonance angiography to detect unruptured intracranial aneurysms. This study aims to identify individuals who are at increased risk and determine the effect of environmental factors for development of unruptured intracranial aneurysms.

Read the detailed description

The prevalence of intracranial aneurysms is 3-5% according to studies, while the annual incidence of complications in the form of bleeding from an intracranial aneurysm is 8-10 per 100 000 people. Subarachnoid hemorrhage is an urgent condition characterized by the extravasation of blood into the space surrounding the central nervous system, which is filled with cerebrospinal fluid. The leading cause of non-traumatic subarachnoid hemorrhage is the rupture of an intracranial aneurysm, accounting for approximately 80-85% of cases, and it is associated with a high rate of complications and mortality. Therefore, early detection of patients at elevated risk, monitoring, and management of unruptured intracranial aneurysms is of paramount importance.

Data suggest that first-degree relatives of a family member affected have higher risk for developing intracranial aneurysm. Screening in Relatives with Elevated Risk for Unruptured Intracranial Aneurysms is research effort of neurosurgeons and neuroradiologists to identify environmental factors in study population of Vojvodina (Serbia), that contribute to development of intracranial aneurysms. This study will involve at least 150 siblings (first-degree relatives) of patients who suffered aneurysmal stroke, and determine effect of demographics, environmental factors including, smoking, medical comorbidities and hypertension, caffeinated drink consumption, and hard physical work on the development of unruptured intracranial aneurysms (UIAs). This study of affected families and individuals, known as Screening in Relatives with Elevated Risk for Unruptured Intracranial Aneurysms (SIREN) study, is sponsored by Provincial Secretariat of Health of the Autonomous Province of Vojvodina (Special Screening Program).

This study will also involve at least 150 individuals with no past family history of aneurysmal stroke or UIAs. SIREN study will take part in Autonomous Province in Vojvodina only.

In order to be eligible for the study, individuals with affected family member that was admitted to study center for aneurysmal stroke, had to be older than 30 years of age, and first-degree relatives (father, mother, sister, brother, daughter, or son).

Participants will be asked to complete informed consent and questionnaire with past medical and family history. After completing questionnaires, their arterial blood pressure will be measured. Participants will receive no monetary compensation for participation.

Identification of demographic and environmental risk factors contributing to development of UIAs in families of affected individuals may result in early detection of ones at risk and potentially prevent formation of UIAs or complications including aneurysmal stroke.

02

Conditions studied

  • Intracranial Aneurysms
  • Subarachnoid Hemorrhage, Aneurysmal

Keywords

  • Stroke
  • Intracranial Aneurysm
  • Brain Aneurysm
  • Familial Intracranial Aneurysm
  • Aneurysmal Subarachnoid Hemorrhage
03

In context

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

University of Novi Sad is the lead sponsor of 28 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enroll first-degree relatives of patients with aneurysmal stroke who are aged 30 years or older, current smokers or have hypertension and individuals with sporadic UIAs and no past family history of aneurysmal stroke or UIAs. Participants must be able to undergo magnetic resonance angiography (MRA) and provide informed consent. Individuals with a prior intracranial aneurysm rupture, contraindications to MRI/MRA, pregnancy, or history of polycystic kidney disease, Marfan's Syndrome, Ehlers Danlos Syndrome, or fibromuscular dysplasia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. First-degree relatives (parents, siblings, or children) of patients diagnosed with aneurysmal subarachnoid hemorrhage (aSAH);
  2. Age ≥ 30 years at the time of enrollment, and current cigarette smokers or diagnosed with hypertension (either treated or untreated);
  3. Able and willing to undergo magnetic resonance angiography (MRA);

5. Able to provide written ; 6. Sporadic aneurysm subjects must have a confirmed UIAs

Exclusion criteria

Exclusion Criteria:

  1. History of intracranial aneurysm rupture or prior subarachnoid hemorrhage;
  2. to MRI/MRA (e.g., pacemaker, metallic implants, severe claustrophobia) or pregnancy (due to MRI safety considerations);
  3. A history of polycystic kidney disease, Marfan's Syndrome, Ehlers Danlos Syndrome, or fibromuscular dysplasia;
  4. Unable or unwilling to provide ;
  5. Participation in another interventional study that could interfere with outcomes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Study Group

    150 individuals that are first-degree relatives of affected patients admitted to study center for aneurysmal stroke and 150 individuals with sporadic UIAs

06

What researchers measure

Primary outcomes

  1. Detection of unruptured intracranial aneurysms by magnetic resonance angiography (MRA).

    The proportion of screened first-degree relatives (aged ≥30) who are found to have one or more UIAs.

    Time frame: At the time of screening (single MRA examination)

Secondary outcomes

  1. Correlation of aneurysm presence with risk factors

    Analysis of the association between demographic and environmental (e.g., age, ethnicity, cigarette smoking, hypertension, consumption of caffeinated drinks, etc.) and the presence of UIAs.

    Time frame: At the time of screening

  2. Aneurysm size and location

    Characterization of detected aneurysms by maximal size (millimeters) and anatomical location within the cerebral vasculature.

    Time frame: At the time of screening

  3. Prevalence of multiple aneurysms

    Proportion of participants with multiple intracranial aneurysms (MIAs) detected on MRA. MIAs are defined as more than one UIAs in one patient.

    Time frame: At the time of screening

  4. Assessment of anatomical variations of cerebral arteries

    Identification and classification of anatomical variations (e.g., vessel hypoplasia, fenestrations, duplicated arteries, circle of Willis variations, etc.) and evaluation of their association with the presence of UIAs.

    Time frame: At the time of screening

07

Study locations

1 site
  • University Clinical Center of Vojvodina
    Novi Sad, Vojvodina 21137, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jan 2027, 11 months later.

Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 11 months is below that.

Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 4, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387575
Lead sponsor
University of Novi Sad
Collaborators
Clinical Center of Vojvodina
Responsible party
Nebojsa Lasica (Medical Doctor, University of Novi Sad) — Principal investigator
First posted
Feb 4, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Nebojsa M Lasica, M.D.
principal investigator · University of Novi Sad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion